

Financial news for RPRX dated on 2018-01-26: Repros Therapeutics Reports Negative Opinion From EMA For Enclomiphene

Financial news for RPRX dated on 2018-01-02: Repros Therapeutics 13G Filing From MMCAP Int'l. Shows New 8.48% Stake

Financial news for RPRX dated on 2017-12-15: UPDATE: Repros Therapeutics Receives Feedback A Negative Opinion Is Likely To Be Received From the CHMP In January Regarding Enclomiphene

Financial news for RPRX dated on 2017-12-15: Repros Highlights Feedback Following Oral Explanation With EMA

Financial news for RPRX dated on 2017-12-13: Wall Street's M&A Chatter From December 12: Fox-Disney, Repros Therapeutics-Allergan, Agrium-Macrofertil

Financial news for RPRX dated on 2017-12-12: A Peek Into The Markets: U.S. Stock Futures Mostly Higher Ahead Of Fed Meeting

Financial news for RPRX dated on 2017-12-12: Repros Therapeutics Acquired by Allergan for \$0.67/Share Cash

Financial news for RPRX dated on 2017-11-13: Repros Therapeutics Reports Q3 EPS \$(0.04) vs \$(0.28) Est., Sales \$304K vs \$0.00 Est.

Financial news for RPRX dated on 2017-10-23: 35 Biggest Movers From Friday

Financial news for RPRX dated on 2017-10-18: 32 Biggest Movers From Yesterday

Financial news for RPRX dated on 2017-08-14: Mid-Afternoon Market Update: Crude Oil Down 2%; Neff Shares Spike Higher

Financial news for RPRX dated on 2017-08-14: 15 Biggest Mid-Day Losers For Monday

Financial news for RPRX dated on 2017-08-14: Repros Therapeutics Reports Q2 EPS \$(0.08) vs \$(0.18) In Same Qtr. Last Year, Sales \$7K vs \$15K YoY

Financial news for RPRX dated on 2017-07-24: 13G From Rosalind Advisors On Repros Therapeutics Shows 5.7% Stake

Financial news for RPRX dated on 2017-07-24: S-3 From Repros Therapeutics Shows Registration For 4.488M Shares Of Common Stock

Financial news for RPRX dated on 2017-07-17: Repros Therapeutics Says its Proellex Program will Remain on Partial Clinical Hold, FDA Indicated Repros Will Need to Compile a Large Pre-Approval Safety Database for Future Development

Financial news for RPRX dated on 2017-05-18: Repros Reports Pricing of \$3.0M Public Offering

Financial news for RPRX dated on 2017-05-17: Repros Therapeutics Reports Offering of Common Stock, Warrants, No Terms Disclosed

Financial news for RPRX dated on 2017-05-09: Repros Therapeutics Q1 EPS \$(0.22) vs \$(0.14) Est., Sales \$7K vs \$17K

Financial news for RPRX dated on 2017-04-10: Repros Therapeutics to Resume Trading at 9:50 AM ET

Financial news for RPRX dated on 2017-04-10: Repros Therapeutics Shares to Resume Trade at 9:50 a.m. EDT

Financial news for RPRX dated on 2017-04-10: Repros Names Dr. Larry Dillaha Permanent CEO

Financial news for RPRX dated on 2017-04-10: Repros Therapeutics Holds Meeting With FDA To Discuss Oral Proellex, FDA Confirms That Proellex To Remain On Partial Clinical Hold While They Consult With Liver Experts Within FDA Regarding Previously Disclosed Effects

Financial news for RPRX dated on 2017-03-31: Repros Therapeutics Reports Q4 EPS \$(0.16) vs \$(0.17) Est., Sales \$47K

Financial news for RPRX dated on 2017-02-02: Repros Names Dr. Larry Dillaha Interim CEO

Financial news for RPRX dated on 2017-01-30: Repros Therapeutics Reports FDA Granted End of Phase 2 Meeting to Discuss Phase 3 Requirements for Oral Proellex for Treatment of UF

Financial news for RPRX dated on 2016-12-19: Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex

Financial news for RPRX dated on 2016-12-12: Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex

Financial news for RPRX dated on 2016-12-06: Repros Announces FDA Advisory Committee Discusses Clinical Trial Designs for Obesity-Related Hypogonadism

Financial news for RPRX dated on 2016-11-16: Repros Therapeutics Shares Rally Following Ladenburg Upgrade To Buy, Positive Data

Financial news for RPRX dated on 2016-11-16: Benzinga's Top Upgrades

Financial news for RPRX dated on 2016-11-16: 20 Stocks Moving In Wednesday's Pre-Market Session

Financial news for RPRX dated on 2016-11-16: Ladenburg Thalmann Upgrades Repros Therapeutics Inc. - Common Stock to Buy

Financial news for RPRX dated on 2016-11-15: Repros Therapeutics Higher Off Positive Data For Proellex

Financial news for RPRX dated on 2016-11-15: 20 Stocks Moving In Tuesday's Pre-Market Session

Financial news for RPRX dated on 2016-11-14: Repros Reports Topline Positive Clinical Data For Proellex

Financial news for RPRX dated on 2016-11-08: Repros Therapeutics Reports Q3 EPS \$(0.17) vs \$(0.18) Est., Sales \$10K

Financial news for RPRX dated on 2016-10-31: 10 Stocks That Plummeted The Past Three Days On Increasing Volume

Financial news for RPRX dated on 2016-10-05: Repros Reports Acceptance Of Dossier For Enclomiphene For Secondary Hypogonadism By European Activities

Financial news for RPRX dated on 2016-09-30: 16 Stocks Moving In Friday's Pre-Market Session

Financial news for RPRX dated on 2016-09-26: Repros Therapeutics Reports Advisory Committee Meeting To Discuss Secondary Hypogonadism

Financial news for RPRX dated on 2016-09-12: Repros Therapeutics Reports Submission of MAA to EMA for Enclomiphene for Treatment of Secondary Hypogonadism

Financial news for RPRX dated on 2016-09-08: 15 Biggest Mid-Day Gainers For Thursday

Financial news for RPRX dated on 2016-09-08: Mid-Day Market Update: Crude Oil Up 3.5%; Tractor Supply Shares Decline Following Weak Forecast

Financial news for RPRX dated on 2016-09-08: Mid-Morning Market Update: Markets Open Lower; Navistar Posts Wider Loss

Financial news for RPRX dated on 2016-09-08: 18 Stocks Moving In Thursday's Pre-Market Session

Financial news for RPRX dated on 2016-09-07: 6 After-Hours Movers: Clinical Trials, Earnings & Public Offerings

Financial news for RPRX dated on 2016-08-09: Repros Therapeutics Reports Q2 EPS \$(0.18) vs. Est. \$(0.20)

Financial news for RPRX dated on 2016-07-19: Repros Therapeutics Releases Presentation on Enclomiphene

Financial news for RPRX dated on 2016-06-02: Mid-Afternoon Market Update: U.S. Stocks Turn Positive; American Woodmark Shares Fall On Earnings Miss

Financial news for RPRX dated on 2016-06-02: Mid-Day Market Update: Conn's Drops Following Weak Q1 Results; Achaogen Shares Surge

Financial news for RPRX dated on 2016-06-02: Mid-Morning Market Update: Markets Open Lower; Joy Global Profit Tops Expectations

Financial news for RPRX dated on 2016-06-02: Top 10 Pre-Market Gainers From Thursday

Financial news for RPRX dated on 2016-06-01: UPDATE: Repros Says 3-Month Interim Results Showed Statistically Significant Increases in Testosterone

Financial news for RPRX dated on 2016-06-01: UPDATE: Repros Says EU Submission of Enclomiphene On Track for Registration Decision in Fall '17

Financial news for RPRX dated on 2016-06-01: Repros Therapeutics Offers Update on EU Submission of Enclomiphene for Treatment of Secondary Hypogonadism, 3-Month Interim Results for Enclomiphene Study

Financial news for RPRX dated on 2016-05-19: 15 Stocks Moving In Thursday's Pre-Market Session

Financial news for RPRX dated on 2016-05-18: UPDATE: Repros Says Primary Endpoint of Induction of Amenorrhea Met for Pooled Oral Doses Compared to Placebo

Financial news for RPRX dated on 2016-05-18: Repros Reports Positive Clinical Data for Oral Proellex(r) in Women With Severe Menstrual Bleeding Due to Uterine Fibroids

Financial news for RPRX dated on 2016-05-16: Repros Names Patrick Fourteau as Chair

Financial news for RPRX dated on 2016-05-10: Repros Therapeutics Reports Q1 EPS \$(0.20) vs \$(0.22) Est., Sales \$17K vs \$1K in Same Qtr. Last Year

Financial news for RPRX dated on 2016-04-19: Repros Therapeutics Spikes to High of \$3.45 on Volume

Financial news for RPRX dated on 2016-04-19: Repros Therapeutics +12.9% Premarket @\$3.15

Financial news for RPRX dated on 2016-04-14: Traders Recently Taking Profits in Repros Therapeutics Below \$2.80 Level, Stock Now Down from High Over \$3.25 Afternoon High to \$2.53

Financial news for RPRX dated on 2016-04-14: Repros Therapeutics Selling Off on Volume

Financial news for RPRX dated on 2016-04-14: Repros Therapeutics Falls To \$2.77/Share

Financial news for RPRX dated on 2016-04-14: Adam Feuerstein @adamfeuerstein Tweet: I'm not interested in how \$RPRX trades. Couldn't care less. I've covered the co. for years. I know the history. Not pretty.

Financial news for RPRX dated on 2016-04-14: Mid-Morning Market Update: Markets Edge Lower; Bank of America Posts Drop In Q1 Profit

Financial news for RPRX dated on 2016-04-14: 10 Stocks Moving In Thursday's Pre-Market Session

Financial news for RPRX dated on 2016-04-14: Repros Therapeutics +24.44% Premarket @\$2.80

Financial news for RPRX dated on 2016-04-13: Mid-Afternoon Market Update: Dow Rises Over 1%; Medivation Shares Gain On Reported Pushback Of Sanofi Takeover Effort

Financial news for RPRX dated on 2016-04-13: The Next Biotech Wonder Stock: Repros Therapeutics?

Financial news for RPRX dated on 2016-04-13: Mid-Day Market Update: Repros Therapeutics Jumps Following Encouraging Study Results; Clovis Oncology Shares Drop

Financial news for RPRX dated on 2016-04-13: 10 Stocks Moving In Wednesday's Pre-Market Session

Financial news for RPRX dated on 2016-04-13: Repros Therapeutics Surges 60% Following Encouraging Study Results

Financial news for RPRX dated on 2016-04-12: Repros Therapeutics Spikes to High of \$1.38 After-Hours

Financial news for RPRX dated on 2016-03-15: Repros Therapeutics Formally Activates Process For Obtaining Marketing Authorization For Enclomiphene

Financial news for RPRX dated on 2016-03-14: Repros Therapeutics Reports Q4 EPS \$(0.26) vs \$(0.27) Est., Sales \$8K vs \$3K in Same Qtr. Last Year

Financial news for RPRX dated on 2016-02-08: Repros Holds Meeting With FDA, Says It Is Clear FDA No Closed To Entering Secondary Hypogonadism As An Indication

Financial news for RPRX dated on 2016-01-11: Repros Reports Court Of Appeals Affirmation Of Summary Judgement In Favor Of Company

Financial news for RPRX dated on 2016-01-07: CEO Podolski Buys 11,677 Shares of Repros Therapeutics @\$1.18/Share -Form 4

Financial news for RPRX dated on 2016-01-04: UPDATE: Repros Says MAA for Enclomiphene Planned for Submission in Europe Mid-'16

Financial news for RPRX dated on 2016-01-04: UPDATE: Repros Says Expects to Meet with FDA to Discuss CRL for Enclomiphene NDA During Feb. '16

Financial news for RPRX dated on 2016-01-04: Repros Therapeutics Issues Update on Enclomiphene Program

Financial news for RPRX dated on 2015-12-21: UPDATE: Topline Results For Repros After 4 Months Of Treatment From All 3 Proellex Trials To Be Available By End Of Q3 2016

Financial news for RPRX dated on 2015-12-21: Repros Updates Proellex Program

Financial news for RPRX dated on 2015-12-01: Shares of Repros Resume, Stock Plunges 40+% to ~\$1.37

Financial news for RPRX dated on 2015-12-01: Shares of Repros Therapeutics to Resume Trade at 10:20 a.m. EST

Financial news for RPRX dated on 2015-12-01: UPDATE: Repros Says FDA Letter Showed Design of Enclomiphene Phase 3 Studies No Longer Adequate to Show Clinical Benefit

Financial news for RPRX dated on 2015-12-01: Repros Reports Receiving CRL from FDA Related to Enclomiphene

Financial news for RPRX dated on 2015-12-01: Reprox Therapeutics Shares Halted News Pending

Financial news for RPRX dated on 2015-11-27: Option Alert: \$RPRX Dec \$3 Call Sweep; 600 Contracts @ Ask @\$0.30; Ref \$2.51

Financial news for RPRX dated on 2015-11-27: Repros Therapeutics +52% @\$2.67

Financial news for RPRX dated on 2015-11-23: Repros Therapeutics Spikes to High

Financial news for RPRX dated on 2015-11-09: Repros Therapeutics Reports Q3 EPS \$(0.27) vs. Est. \$(0.29)

Financial news for RPRX dated on 2015-10-29: Reporos -53% as FDA Cancels Review of Hypogonadism Drug

Financial news for RPRX dated on 2015-10-29: Shares of Repros to Resume Trade at 3:40 p.m. EDT

Financial news for RPRX dated on 2015-10-29: UPDATE: Repros Says Cancellation Related to 'questions that arose late in the review regarding the bioanalytical method validation...'

Financial news for RPRX dated on 2015-10-29: Repros Reports Cancellation of FDA Panel Meeting to Review Enclomiphene

Financial news for RPRX dated on 2015-10-29: Repros Therapeutics Halted News Pending

Financial news for RPRX dated on 2015-10-21: Mid-Day Market Update: Crude Oil Drops Over 2%; KLA-Tencor Shares Jump On Acquisition News

Financial news for RPRX dated on 2015-08-10: Repros Therapeutics Says R&D Expenses Dropped 14% In Past Three Months, Cites Completion Of Phase 3 Clinical Trials For Enclomiphene Product As Reason

Financial news for RPRX dated on 2015-08-10: Repros Therapeutics Reports Q2 Loss of \$0.32/Share vs Loss of \$0.26/Share Est., Sales \$1K

Financial news for RPRX dated on 2015-08-05: Option Alert: Repros Nov \$9 Call; 2000 Contracts @Ask @\$2.25

Financial news for RPRX dated on 2015-04-06: Repros Receives Confirmation of Eligibility for Submission of a Centralized Marketing Authorization Application to the European Medicines Agency as a New Active Substance

Financial news for RPRX dated on 2015-04-02: Morning Market Gainers

Financial news for RPRX dated on 2015-04-01: Repros Announces Acceptance for Filing of NDA

Financial news for RPRX dated on 2015-03-16: Repros Therapeutics Reports Q4 EPS -\$0.31 Vs Est -\$0.34, Sales \$3K

Financial news for RPRX dated on 2015-03-16: Earnings Scheduled For March 16, 2015

Financial news for RPRX dated on 2015-02-02: Repros Submits New Drug Application to FDA for Androxal

Financial news for RPRX dated on 2014-12-30: Morning Market Movers

Financial news for RPRX dated on 2014-12-30: Benzinga's Top #PreMarket Gainers

Financial news for RPRX dated on 2014-12-30: Keep an Eye on These 5 Stocks for December 30, 2014

Financial news for RPRX dated on 2014-12-29: Post-Market Movers for Dec. 29: XNPT, RPRX, ACN Higher; CVEO, JST Lower

Financial news for RPRX dated on 2014-12-29: Repros Initiates Two Phase 2B Uterine Fibroid Studies

Financial news for RPRX dated on 2014-12-29: Court Rules Inventors Correctly Named on Androxal Patents

Financial news for RPRX dated on 2014-12-26: Markman Advisors LLC @MarkmanAdvisors Tweet \$RPRX Clean win - Fisch is not a co-inventor as a matter of law on \$RPRX's patents, Fisch's claims were equitably estopped. Trial averted.

Financial news for RPRX dated on 2014-12-08: How To Profit From The Obesity Epidemic

Financial news for RPRX dated on 2014-12-08: Pharmaceutical Stocks In Play Following Merck/Cubist Deal

Financial news for RPRX dated on 2014-11-11: Brean Capital Sees No Surprises In 3Q14 Report For Repros Therapeutics

Financial news for RPRX dated on 2014-11-10: Repros Therapeutics opens down on heavy volume. RPRX shares down 47% YTD basis

Financial news for RPRX dated on 2014-11-10: Morning Market Losers

Financial news for RPRX dated on 2014-11-10: Repros Therapeutics Inc. Reports Q3 EPS of \$(0.32) vs \$(0.39) Est

Financial news for RPRX dated on 2014-11-07: Repros Shares Rise 44% on Report of Constructive Meeting With FDA Regarding Androxal NDA Filing

Financial news for RPRX dated on 2014-11-07: Morning Market Movers

Financial news for RPRX dated on 2014-11-06: Repros Holds Constructive Meeting With FDA Regarding Androxal NDA Filing

Financial news for RPRX dated on 2014-11-06: Repros Holds Constructive Meeting With FDA Regarding Androxal NDA Filing; Says No New Clinical Studies Requested

Financial news for RPRX dated on 2014-10-21: Results From Long-Term Study of Androxal(R) Exhibit Positive Safety Profile

Financial news for RPRX dated on 2014-10-17: Stocks Hitting 52-Week Lows

Financial news for RPRX dated on 2014-10-17: Morning Market Losers

Financial news for RPRX dated on 2014-10-17: Repros Therapeutics Shares Fall 43% Premarket Following Announcement FDA Meeting Will be Type C Guidance Meeting vs Type B Pre-NDA Meeting

Financial news for RPRX dated on 2014-10-16: Repros Therapeutics Reports Upcoming FDA Meeting to be Type C Meeting

Financial news for RPRX dated on 2014-09-26: Morning Market Movers

Financial news for RPRX dated on 2014-09-26: Benzinga's Top #PreMarket Gainers

Financial news for RPRX dated on 2014-09-26: US Stock Futures Rise Ahead Of GDP, Consumer Sentiment Data

Financial news for RPRX dated on 2014-09-26: Repros Says FDA Schedules Type B Pre-NDA Meeting in First Half of November

Financial news for RPRX dated on 2014-09-26: Repros Therapeutics Shares Rise 15% Premarket Following Announcement Androxal ZA-304 Study Met Primary Endpoint

Financial news for RPRX dated on 2014-09-25: Repros Therapeutics Announces Androxal ZA-304 Study Met Primary Endpoint

Financial news for RPRX dated on 2014-09-24: Option Alert: Repros Therapeutics Shares Move Higher; Activity in Jan \$17.5 Call; Currently \$8.99

Financial news for RPRX dated on 2014-09-22: Repros Gives Update On Androxal With Respect To Recent FDA Advisory Panel Outcome And Announces Upcoming Presentation at BioCentury

Financial news for RPRX dated on 2014-09-17: FDA Spokesperson Confirms FDA Advisory Panel Has Voted 20-1 FDA Should Revise Approved Uses of Testosterone Treatments

Financial news for RPRX dated on 2014-09-17: Several Sources on Twitter Suggesting FDA Advisory Panel Has Voted 20-1 FDA Needs to Revise Approved Uses for Testosterone Drugs

Financial news for RPRX dated on 2014-09-12: Option Alert: Repros Therapeutics Shares Move Higher; Activity in Sep \$17.5 Call; Currently \$14.57

Financial news for RPRX dated on 2014-09-11: Option Alert: Repros Therapeutics Shares Move Higher; Activity in Sep \$17.5 Call; Currently \$15.01

Financial news for RPRX dated on 2014-09-05: Infoblox Inc Gains On Upbeat Results; The Gap Inc. Shares Decline

Financial news for RPRX dated on 2014-09-03: Piper Jaffray Downgrades Repros Therapeutics Inc. to Neutral, Lowers PT to \$24.00

Financial news for RPRX dated on 2014-08-29: UPDATE: Ascendant Capital Markets Reiterates On Repros Therapeutics Following Positive Topline Results

Financial news for RPRX dated on 2014-08-28: Williams-Sonoma Dips On Downbeat Q3 Forecast; Signet Jewelers Shares Jump

Financial news for RPRX dated on 2014-08-28: Markets Open Lower; Dollar General Profit Matches Street View

Financial news for RPRX dated on 2014-08-28: Benzinga's Volume Movers

Financial news for RPRX dated on 2014-08-28: Morning Market Movers

Financial news for RPRX dated on 2014-08-28: Repros Therapeutics Selloff Sharply from \$21.80 High in Premarket, Now Down 3%; Co Reported Positive Top Line Results from Androxal Studies on Wednesday

Financial news for RPRX dated on 2014-08-27: Repros Therapeutics Reports Positive Top Line Results from Androxal Studies

Financial news for RPRX dated on 2014-08-27: Androxal Achieves Superiority In Top Line Analysis For Both Co-Primary Endpoints And Various Secondary Endpoints

Financial news for RPRX dated on 2014-08-11: Earnings Scheduled For August 11, 2014

Financial news for RPRX dated on 2014-07-16: FDA Confirms Endpoints of Androxal Study

Financial news for RPRX dated on 2014-05-13: UPDATE: Repros Says Timing of Androxal Study Completion Likely to Allow NDA Submission in Q4

Financial news for RPRX dated on 2014-05-13: Repros Reports Has Fully Enrolled Second Previously-Announced Head-to-Head Study of Androxal, Sees Topline Results by Q4

Financial news for RPRX dated on 2014-05-12: Repros Therapeutics Inc. Reports Q1 EPS of \$(0.37) vs \$(0.35) Est

Financial news for RPRX dated on 2014-04-14: Repros Therapeutics Announces Full Enrollment of First of Two Studies of Androxal(R) Compared to Gel, Expecting to File NDA in Q4'14

Financial news for RPRX dated on 2014-04-14: Repros Fully Enrolls First of Two Previously Announced Head to Head Studies of Androxal vs Leading Topical Testosterone Gel

Financial news for RPRX dated on 2014-03-17: UPDATE: Repros to Submit Phase 2 Protocol, Cites FDA Guidance

Financial news for RPRX dated on 2014-03-17: Repros Allowed to Conduct Phase 1 and 2 Clinical Studies of Low Dose Oral Proellex(R) in the Treatment of Uterine Fibroids and Endometriosis

Financial news for RPRX dated on 2014-03-14: Earning and Economic Calendar for Friday March 14, 2014

Financial news for RPRX dated on 2014-03-13: Repros Therapeutics Inc. Reports Q4 EPS of \$(0.31) vs \$(0.29) Est

Financial news for RPRX dated on 2014-02-10: Repros Therapeutics Offers Findings from Six-Month Study of Androxal, Says Greater Than 80% of Men Obtained T-Normal Range, Statistical Significant Reduction in Glucose Compared to Baseline

Financial news for RPRX dated on 2014-02-06: US Stock Futures Surge Ahead Of GM Earnings, Jobless Claims Data

Financial news for RPRX dated on 2014-02-06: Repros Meets With FDA; Expects NDA Submission for Androxal for Treatment of Secondary Hypogonadism by End of 2014

Financial news for RPRX dated on 2013-12-19: Repros Adds Marketing and Commercialization Expertise to Board of Directors

Financial news for RPRX dated on 2013-11-27: UPDATE: Piper Jaffray Initiates Coverage on Repros Therapeutics on a Cleaner Approach to Male Hypogonadism

Financial news for RPRX dated on 2013-11-27: UPDATE: Piper Jaffray Initiates On Repros Therapeutics On Androxal Prospects

Financial news for RPRX dated on 2013-11-26: Piper Jaffray Initiates Coverage on Repros Therapeutics Inc. at Overweight, Announces \$26.00 PT

Financial news for RPRX dated on 2013-11-25: Repros to Present Androxal Data at 9th Men's Health World Congress

Financial news for RPRX dated on 2013-11-25: Repros Granted Face to Face Meeting With FDA to Discuss Androxal Efficacy

Financial news for RPRX dated on 2013-11-19: Laidlaw & Co. Initiates Coverage on Repros Therapeutics Inc. at Buy, Announces \$32.00 PT

Financial news for RPRX dated on 2013-11-04: Repros Receives FDA Guidance for Proellex

Financial news for RPRX dated on 2013-10-24: UPDATE: Ascendant Capital Markets Downgrades Repros Therapeutics Following Announcement of FDA Concerns

Financial news for RPRX dated on 2013-10-23: Ascendant Capital Downgrades Repros Therapeutics Inc. to Buy, Maintains \$25.00 PT

Financial news for RPRX dated on 2013-10-22: Repros Receives FDA Guidance Regarding Clinical Program for Androxal

Financial news for RPRX dated on 2013-09-27: Repros Therapeutics Files Slideshow Ahead of BioCentruy Biotech Conference (at 2PM EDT): Says Modeling for FY16 Sales \$92M

Financial news for RPRX dated on 2013-09-18: Repros Issues Added Info Confirming Success for Study ZA-302, Says SPA Met Co-Primary Endpoints

Financial news for RPRX dated on 2013-09-18: Benzinga's Volume Movers

Financial news for RPRX dated on 2013-09-18: Shares of Repros Therapeutics Taking Back Gains Following Yesterday's Mid-day Sell-off from Highs Over \$26, Stock Up 12+% at Last Check, Breaking Out Over \$26

Financial news for RPRX dated on 2013-09-18: UPDATE: Bank of America Raises PT on Repros Therapeutics on Higher Androxal Conviction

Financial news for RPRX dated on 2013-09-17: Bank of America Maintains Buy on Repros Therapeutics Inc., Raises PO to \$35.00

Financial news for RPRX dated on 2013-09-17: Market Wrap for Tuesday, September 17: Metals All Down, Repros Therapeutics Gives Back Mostly All Gains

Financial news for RPRX dated on 2013-09-17: Mid-Afternoon Market Update: Markets

Topping Out as Berry Plastics Gets Crushed on Poor Guidance

Financial news for RPRX dated on 2013-09-17: Option Alert: Repros Therapeutics October 25 Call; 2,800 Contracts Traded @\$1.85; Currently \$22.67

Financial news for RPRX dated on 2013-09-17: Mid-Morning Market Update: Markets Open Higher; FactSet Research Posts Downbeat Q4 Earnings

Financial news for RPRX dated on 2013-09-17: Benzinga's Volume Movers

Financial news for RPRX dated on 2013-09-17: Stocks Hitting 52-Week Highs

Financial news for RPRX dated on 2013-09-17: Morning Market Movers

Financial news for RPRX dated on 2013-09-16: Repros Reports Androxal Meets Both Co-Primary Endpoints in Second Pivotal Study ZA-302

Financial news for RPRX dated on 2013-09-04: Option Alert: Repros Therapeutics October 25 Call; 4,000 Contracts Traded @\$3.06, Currently \$22.89

Financial news for RPRX dated on 2013-08-07: Repros Therapeutics Inc. Reports Q2 EPS of \$(0.38) vs \$(0.40) Est

Financial news for RPRX dated on 2013-08-05: Repros Therapeutics Falls on TheStreet.com Article Company Worried About Validity of Androxal Patent

Financial news for RPRX dated on 2013-08-05: Repros Seeks to Affirm Its Intellectual Property Rights in Androxal(R)

Financial news for RPRX dated on 2013-07-29: Brean Capital Initiates Coverage on Repros Therapeutics Inc. at Buy, Announces \$32.00 PT

Financial news for RPRX dated on 2013-07-09: Slideshow in Repros Therapeutics 8-K Show Co. Sees FY15 Sales \$5M, FY16 Sales \$63M, EBITDA \$14M in 2016

Financial news for RPRX dated on 2013-07-02: UPDATE: Bank of America Initiates Repros Therapeutics with Buy on Androxal Potential

Financial news for RPRX dated on 2013-07-02: Bank of America Initiates Coverage on Repros Therapeutics Inc. at Buy, Announces \$25.00 PO

Financial news for RPRX dated on 2013-06-19: Repros Therapeutics Prices 3.75M Share Offering at \$19.00/Share

Financial news for RPRX dated on 2013-06-17: Repros Therapeutics Announces offering of 3,000,000 Shares

Financial news for RPRX dated on 2013-05-22: FDA Recommends Running Phase 2b Trial of Repros' Proellex-V

Financial news for RPRX dated on 2013-05-10: Repros Therapeutics Inc. Reports Q1 EPS of \$(0.41) vs \$(0.35) Est

Financial news for RPRX dated on 2013-04-18: Stocks to Watch for April 18, 2013

Financial news for RPRX dated on 2013-03-28: Morning Market Movers

Financial news for RPRX dated on 2013-03-28: Repros Therapeutics Rises 56% Pre-Market on Successful Androxal Study

Financial news for RPRX dated on 2013-03-27: Repros Reports Both Primary Endpoints Successfully Met in Androxal Study

Financial news for RPRX dated on 2013-03-18: Repros Therapeutics Inc. Reports Q4 EPS of \$(0.47) vs \$(0.28) Est

Financial news for RPRX dated on 2013-02-28: Repros Therapeutics Says FDA Granted End of Phase 2 Meeting in Late May to Discuss Proellex(R)-V Phase 2 Design

Financial news for RPRX dated on 2013-02-21: Market Wrap for Thursday, February 21: Stocks Fall For Second Day

Financial news for RPRX dated on 2013-02-21: A Peek Into The Market Before The Trading Starts

Financial news for RPRX dated on 2013-02-21: Repros Says FDA Recommends Pivotal Study ZA-301 of Androxal to be Completed as Originally Planned

Financial news for RPRX dated on 2013-02-20: SAC Capital Showing 5.2% Passive Stake

in Repros Therapeutics

Financial news for RPRX dated on 2013-02-05: Lazard Initiated Coverage on Vanda Pharma with a Buy Rating, \$11 Price Target, Neurocrine Biosciences with a Buy and \$13 PT, Repros Therapeutics with Buy, \$26 PT

Financial news for RPRX dated on 2013-02-05: Benzinga's Top Initiations

Financial news for RPRX dated on 2013-01-29: Ascendant Capital Maintains Strong Buy on Repros Therapeutics Inc., Lowers PT to \$19.00

Financial news for RPRX dated on 2013-01-28: Morning Market Losers

Financial news for RPRX dated on 2013-01-28: Repros Therapeutics Offers Update to Top-Line Results Guidance from First Pivotal Study of Androxal

Financial news for RPRX dated on 2013-01-08: Ascendant Capital Maintains Strong Buy on Repros Therapeutics Inc., Raises PT to \$20.00

Financial news for RPRX dated on 2013-01-07: Repros Therapeutics Announces Core One-Year DEXA Study Full Enrolled Ahead of Schedule, Offers Update for Androxal Clinical Program

Financial news for RPRX dated on 2013-01-03: Repros Therapeutics Offers Topline Results from Phase 2 Study of Proellex for Uterine Fibroids

Financial news for RPRX dated on 2012-11-21: From Earlier: Roth Capital Initiates Coverage on Repros Therapeutics at Buy, Announces PT of \$19

Financial news for RPRX dated on 2012-11-13: Repros Therapeutics Reports EPS \$-0.30 vs \$-0.24 Est

Financial news for RPRX dated on 2012-10-08: Repros Therapeutics Says Will Proceed with Phase 2 Study on Endometriosis; Says Data Should Allow Partial Clinic Hold Removed

Financial news for RPRX dated on 2012-09-19: Repros Therapeutics Spikes Higher

Financial news for RPRX dated on 2012-09-12: Repros Therapeutics Says Results from First Study Could be Available in Q2, has Sufficient Funds to Submit Androxal NDA in 2014

Financial news for RPRX dated on 2012-09-05: Repros Therapeutics Spikes to 52-Week Highs

Financial news for RPRX dated on 2012-09-04: Repros Therapeutics Falls 8% on Offering

Financial news for RPRX dated on 2012-09-04: Repros Therapeutics Resumes Trading

Financial news for RPRX dated on 2012-09-04: PREVIEW: Repros Therapeutics to Resume Trading at 4:30pm

Financial news for RPRX dated on 2012-09-04: Repros Announces the Offering of Unregistered Shares of Common Stock in the Amount of \$23.6M at \$11.00/Share

Financial news for RPRX dated on 2012-09-04: Repros Therapeutics Halted Pending News

Financial news for RPRX dated on 2012-08-27: Repros Therapeutics Says FDA Provided Guidance for Phase 2 Study of Proellex

Financial news for RPRX dated on 2012-08-15: Ascendant Capital Markets Maintains Repros Therapeutics at Strong Buy, Raises PT from \$10 to \$12

Financial news for RPRX dated on 2012-08-13: Repros Therapeutics Reports Q2 EPS \$-0.21 vs \$-0.19 Est

Financial news for RPRX dated on 2012-07-30: FDA Requests Teleconference to Discuss Repros Phase 2 Protocol for Proellex(R) in the Treatment of Endometriosis Last Week of August

Financial news for RPRX dated on 2012-07-23: Repros' Proellex(R)-V Shows Consistent Efficacy in Uterine Fibroids Phase 2 Study

Financial news for RPRX dated on 2012-07-16: Repros Therapeutics up 5% After FDA Provides Guidance on clinical Hold of Proellex

Financial news for RPRX dated on 2012-07-16: FDA Provides Guidance to Repros for the Conduct of a Phase 2 Study of Low Dose Oral Proellex in the Treatment of Endometriosis

Financial news for RPRX dated on 2012-07-09: FDA Accepts Repros' Phase 3 Efficacy Protocol for Androxal(R) Under a Special Protocol Assessment Agreement

Financial news for RPRX dated on 2012-06-18: Repros Receives Official FDA Minutes for Androxal Phase 3 Meeting Held on May 9, 2012; Believes Minutes Confirm FDA Requirements for NDA

Financial news for RPRX dated on 2012-06-07: Ten Analyst Calls That Made You 60-Plus Percent in 2012

Financial news for RPRX dated on 2012-05-29: Repros Updates Status of Proellex Clinical Programs; Phase 2 Vaginal Proellex(r)-V, ZPV-200, Study on Track for Full Enrollment by End of June

Financial news for RPRX dated on 2012-05-25: Repros Therapeutics Spikes to 52-Week Highs, \$8.68

Financial news for RPRX dated on 2012-05-24: 3 Top Small-Cap Performers Over the Last Month

Financial news for RPRX dated on 2012-05-22: Repros Updates Special Protocol Assessment Documentation for Pivotal Studies for Androxal

Financial news for RPRX dated on 2012-05-21: The Strongest Small-Caps in the Market

Financial news for RPRX dated on 2012-05-16: FDA Receives Repros' Submission for Special Protocol Assessment Documentation for Pivotal Studies for Androxal

Financial news for RPRX dated on 2012-05-16: Ascendant Capital Markets Maintains Repros Therapeutics at Strong Buy, Raises PT from \$7 to \$10

Financial news for RPRX dated on 2012-05-15: Ladenburg Thalmann Maintains Repros Therapeutics at Buy, Raises PT from \$10 to \$13.5

Financial news for RPRX dated on 2012-05-14: Repros Therapeutics Trading Near 52-Week High; Currently at \$7.9

Financial news for RPRX dated on 2012-05-11: Repros Therapeutics Trading 34% Higher on Heavy Volume; Currently at \$7.37

Financial news for RPRX dated on 2012-04-10: UPDATE: Ascendant Initiates Coverage on Repros Therapeutics

Financial news for RPRX dated on 2012-04-10: Ascendant Capital Markets Initiates Coverage on Repros Therapeutics at Strong Buy, Announces PT of \$6

Financial news for RPRX dated on 2012-02-27: FDA Grants Repros Meeting to Discuss Androxal Phase 3 Study Design and Required Drug Dossier for NDA

Financial news for RPRX dated on 2012-02-03: Repros Announces the Closing of a Registered Direct Offering of Approximately \$11.1M

Financial news for RPRX dated on 2012-01-27: Repros Announces Registered Direct Offering of Approximately \$11.1 Million

Financial news for RPRX dated on 2012-01-13: Repros Therapeutics Files to Withdraw S-1 Filed on December 19, 2011; Had Filed to Sell 5.75M Shares

Financial news for RPRX dated on 2012-01-04: End-of-Day Market Summary for January 4, 2012

Financial news for RPRX dated on 2012-01-04: Repros' IND for Proellex-V Accepted By the FDA

Financial news for RPRX dated on 2011-12-27: Repros Receives Official FDA Minutes From Type C Meeting Held on 12/13/11 Confirming Path Forward for Androxal

Financial news for RPRX dated on 2011-12-27: Men Entering One Year Extension Study of ZA-203 Elect Treatment With Androxal Over Approved Topical Testosterone Product

Financial news for RPRX dated on 2011-12-22: Top-Line Phase 2b Data Indicate Androxal Raises Testosterone Equivalent to Testim Without Impairing Spermatogenesis

Financial news for RPRX dated on 2011-12-14: Repros Meets With the Divisions of Urologic and Endocrinologic Products at FDA to Plan Direction of Phase 3 Program for Androxal

Financial news for RPRX dated on 2011-11-07: Oral Androxal Achieves Equivalent 24

Hour Average Testosterone Levels Compared to Leading FDA Approved Testosterone Gel

Financial news for RPRX dated on 2011-09-12: Repros Completes Enrollment in Three Androxal Studies

Financial news for RPRX dated on 2011-09-08: Repros to Submit IND for Vaginal Delivery of Proellex

Financial news for RPRX dated on 2011-07-22: Repros Therapeutics Spiking Higher on Heavy Volume

Financial news for RPRX dated on 2011-05-02: Repros Therapeutics Provides Clinical Update for Androxal Study in Men With Type 2 Diabetes

Financial news for RPRX dated on 2011-04-28: Top five companies Stocks in the Specialty Chemicals industry- ROC, NLC, CYT, FOE, ECL

Financial news for RPRX dated on 2011-04-26: CEOWORLD Top 15 Stocks Picks Below \$10- RMTR, APP, ACAD, HRZ, AIB, HNSN, QPSA, JRJC, TASR, RPRX, ONTY, LOOK, CT, SHZ, ESLR

Financial news for RPRX dated on 2011-03-28: Repros Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results

Financial news for RPRX dated on 2011-03-16: Repros Therapeutics Commences Dosing Third Cohort in Low Dose Proellex Study

Financial news for RPRX dated on 2011-03-15: Repros Reports Results From Completed 1 mg Dose Cohort in Low Dose Proellex Study

Financial news for RPRX dated on 2011-03-04: Puts Purchased on Repros Therapeutics Inc. (RPRX)

Financial news for RPRX dated on 2011-03-02: Options Brief: Repros Therapeutics (RPRX)

Financial news for RPRX dated on 2011-03-02: NASDAQ Stocks Hitting 52-Week Highs (PEET, RPRX, FEIC, ALXN)

Financial news for RPRX dated on 2011-02-03: Repros Therapeutics Announces Prices Public Offering of Common Stock at \$17.15 per Share

Financial news for RPRX dated on 2010-12-27: 1 Huge Winner, 2 Big Losers (DRYS, XOMA, REPRX)

Financial news for RPRX dated on 2010-12-27: Morning Market Movers (RPRX, PRVT, BPAX, JTX)

Financial news for RPRX dated on 2010-12-27: Repros Therapeutics Up Slightly In Pre-Market (RPRX)

Financial news for RPRX dated on 2010-12-23: Repros Therapeutics Continues Higher (RPRX)

Financial news for RPRX dated on 2010-12-23: Repros Therapeutics Ripping (RPRX)

Financial news for RPRX dated on 2010-12-23: Repros Therapeutics Up Over 30% On FDA Data (RPRX)

Financial news for RPRX dated on 2010-12-16: 5 Pharma Stocks Trading for Under \$2

Financial news for RPRX dated on 2010-11-24: FDA Approves Axiron - Analyst Blog

Financial news for RPRX dated on 2010-11-24: FDA Approves Axiron - Analyst Blog

Financial news for RPRX dated on 2010-09-30: FDA Grants Repros Type B Meeting (RPRX)

Financial news for RPRX dated on 2010-09-29: Repros Board Approves Reverse Stock Split

Financial news for RPRX dated on 2010-08-26: Repros Schedules Meeting with FDA - Analyst Blog

Financial news for RPRX dated on 2009-11-09: Repros Therapeutics Inc. (RPRX) Reports 2009Q3 Financial Results

Financial news for RPRX dated on 2009-10-08: Biggest Losers (VG, RPRX, STC, SVNT, RINO)

Financial news for RPRX dated on 2009-09-21: Biggest Losers (DPTR, ALTI, RPRX, IAG, DELL)

Financial news for RPRX dated on 2009-08-14: Brower Piven Encourages Investors Who Have Losses in Excess of \$50,000 From Investment in Repros Therapeutics, Inc. to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit Before the October 6, 2009 Lead Plaintiff Deadline

Financial news for RPRX dated on 2009-08-10: Federman & Sherwood Announces That a Securities Class Action Lawsuit Has Been Filed Against Repros Therapeutics Inc. (NASDAQ: RPRX)

Financial news for RPRX dated on 2009-08-08: Rosen Law Firm Announces Class Action Lawsuit Against Repros Therapeutics Inc. -- RPRX